Stefano Pierini, MSc; Stanislav H. Jordanov MD; Atanaska V. Mitkova, PhD; Ivan J. Chalakov, MD, PhD; Mincho B. Melnicharov, MD, PhD; Kuncho V. Kunev, MD, PhD; Vanio I. Mitev, MD, PhD; Radka. P Kaneva, PhD, Teodora E. Goranova, PhD; Promoter Hypermethylation of CDKN2A, MGMT, MLH1 and DAPK genes in Laryngeal Squamous Cell Carcinoma and their associations with clinical profiles of the patients. Head and Neck 2014 Aug; 36(8): 1103-8. doi: 10.1002/hed.23413. Epub 2013 Oct 7.
Chung C.H. et al Molecular classification of head and neck squamous cell carcinomas usig paterns of gene expression. Cancer cell 5, 489-500 (2004).
Hopkins. J et al Genetic polymorphism and haed and neck cancer outcomes: a revew. Cancer Epidemiol. Biomark. Prev. 17, 490-499 (2008).
Smeets. S. J. et al. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell. Oncol. 31. 291-300 (2009).
Slaughter, D.P., Southwick, H. W. and Snejkal, W.: Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
Smeets S.J., Braakhuis B.J.M., Abbas S. et al.; Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene (2006) 25, 2558-2564, Nature Publishing Group.
Gao X, Fisher SG, Mohideen N, et al. Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003; 56: 427-35.
Myriam Loyo, Sara I. Pai. The Molecular Genetics of Laryngeal Cancer. Otolaryngol Clin N Am 41 (2008) 657-672.
Nadal A, Cardesa A: Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch 2003, 442(1): 1-7.
Davis CD, Uthus EO: DNA methylation, cancer susceptibility, and nutrient interactions. Experimental biology and medicine (Maywood, NJ 2004, 229(10): 988-995.
Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Human molecular genetics 2007, 16 Spec No 1: R50-59.
Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol 4: 351, 2003.
Futscher B.W., Oshiro M.M., Wozniak R.J., Holtan N., Haniagan C.L., Duan H., Domann F.E. : Role for DNA methylation in the control of cell type specific MASPIN expression. Nat Genet., 31,175-179 (2002).
Feinberg AP, Cui H, Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Seminars in cancer biology 2002, 12(5): 389-398.
Bestor TH. Transposons reanimated in mice. Cell 2005; 122: 322-5.
Costello, J.F., Fruhwald, M.C., Smiraglia, D.J., Rush, L.J., et al. Aberrant CpG-island methylation has non-random and tumortype-specific patterns. Nat. Genet. (2000), 24, 132-138.
Esteller M, Corn P.G., Baylin S.B. and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. (2001), 61, 3225-3229.
Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-4.
Merlo A, Herman JG, Mao L, et al. 5’CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancer. Nat Med 1995; 1: 682-92.
Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-30.
Gonzales-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5’CpG island of p16/CDKN2 tumor suppressor gene in normal and transformed human tissue correlates with gene silencing. Cancer Res 1995; 55: 4531-5.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl. J Med 2003; 349: 2042-54.
Esteller M, Silva JM, Dominiguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
Karpf AR, Matsui S, Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 2005; 65: 8635-9.
Feinberg AP. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 1999; 59:Suppl:1743s-1746s.
Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753-55.
Kaneda A, Feinberg AP. Loss of imprinting of IGF2: common epigenetic modifier of intestinal tumor risk. Cancer Res 2005; 65:11236-40.
Feinberg AP: Genomic imprinting and cancer. In Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer, 2nd edition, New York, McGraw- Hill, 2002, p 43-55.
Puri SK, Si L, Fan CY, Hanna E. Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am. J Otolaryngolog 2005; 26(1): 12-7.
Sasiadek MM, Stembalska-Kozlowska A, Smigiel R, Ramsey D, Kayademir T, blin N. Impairment of MLH1 and CDKN2A in oncogenesis of laryngeal cancer. Br. J Cancer 2004; 90(8): 1594-9.
Wong TS, Gao W, Li ZH, Chan JY, Ho WK. Epigenetic dysregulation in laryngeal squamous cell carcinoma. J Oncol 2012; 2012: 739461.
Makitie AA, Monni O. Molecular profiling of laryngeal cancer. Expert Rev. Anticancer Ther 2009; 9(9): 1251-60.
Hasegawa M, Nelson HH, Peters E, Ringstorm E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21(27): 4231-6.
Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol 2011;47(2):104-7.
Liu K, Huang H, Mukunyadzi P, Suen JY, Hanna E, Fan CY. Promotor hypermethylation: an important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2002; 126(5): 548-53.
Popov TM, Goranova TE, Stancheva G, Kaneva RP, Dikov T, Chalakov I, Rangachev J, Konov D, Todorov S, Stoyanov O, Mitev V (2014) Relative quantitative expression of HIF-1α, HIF-2α, HIF-3α and VEGF-A in laryngeal carcinoma. Oncology Letters.
Willis RA: The spread of Tumors in the Human Body. London, Butterworth & Co, 1952.
